Molecular Templates Inc. (MTEM) and Codexis Inc. (NASDAQ:CDXS) Comparing side by side

We are comparing Molecular Templates Inc. (NASDAQ:MTEM) and Codexis Inc. (NASDAQ:CDXS) on their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Molecular Templates Inc. 9 0.00 20.78M -0.90 0.00
Codexis Inc. 15 -5.15 42.49M -0.21 0.00

Table 1 highlights Molecular Templates Inc. and Codexis Inc.’s gross revenue, earnings per share and valuation.


Table 2 shows us the return on assets, return on equity and net margins of both companies.

Net Margins Return on Equity Return on Assets
Molecular Templates Inc. 233,483,146.07% -30.4% -21.7%
Codexis Inc. 292,832,529.29% -21.1% -13.5%

Risk & Volatility

Molecular Templates Inc. has a beta of 2.73 and its 173.00% more volatile than Standard and Poor’s 500. In other hand, Codexis Inc. has beta of -0.06 which is 106.00% less volatile than Standard and Poor’s 500.


The Current Ratio of Molecular Templates Inc. is 3.2 while its Quick Ratio stands at 3.2. The Current Ratio of rival Codexis Inc. is 3.4 and its Quick Ratio is has 3.4. Codexis Inc. is better equipped to clear short and long-term obligations than Molecular Templates Inc.

Insider & Institutional Ownership

Molecular Templates Inc. and Codexis Inc. has shares held by institutional investors as follows: 72.2% and 92.2%. About 12.75% of Molecular Templates Inc.’s share are held by insiders. Competitively, 3.9% are Codexis Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Molecular Templates Inc. -8.75% -22.34% -8.88% 47.64% 32.46% 62.62%
Codexis Inc. -1.5% -3.26% -6.08% 3.84% 37.09% 10%

For the past year Molecular Templates Inc. has stronger performance than Codexis Inc.


Codexis Inc. beats Molecular Templates Inc. on 8 of the 10 factors.

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.

Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The companyÂ’s platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also improves the pharmaceuticals companies manufacturing productivity and efficiency, as well as helps in outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. Further, the company develops biocatalysts for use in the fine chemicals market, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.